Williams N N, Daly J M
Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia.
Surg Gynecol Obstet. 1990 Sep;171(3):257-66.
Flow cytometric DNA content analysis is a rapid, quantitative method of determining the DNA ploidy status and proliferative index of a given tumor. Abnormal DNA content, or aneuploidy, has been recognized as a marker of malignancy and is present in about 70 per cent of solid tumors. In the majority of solid tumors, the consensus is that the presence of an aneuploid tumor predicts a poorer over-all survival rate and a shorter disease-free interval, indicating that patients with diploid tumors have a more favorable prognosis than those with aneuploid tumors. The prognostic implications of an abnormal DNA content, therefore, suggest either a higher risk of relapse, a worsening of survival rate or a risk for progression of disease in stages I and II carcinoma of the breast, carcinoma of the colon and rectum, superficial carcinoma of the bladder and malignant melanoma. Thus, the assessment of cellular DNA content should be regarded as an additional prognostic determinant and should play an ancillary role in the decisions regarding the management of patients with malignant disease. With the introduction of more sophisticated technology, it will be possible to simultaneously assay for DNA ploidy and cell cycle distribution in addition to a series of tumor markers, such as CEA, and various products of oncogenes, thus providing further understanding of the heterogeneity of solid tumor cells.
流式细胞术DNA含量分析是一种快速、定量的方法，用于确定特定肿瘤的DNA倍体状态和增殖指数。异常的DNA含量，即非整倍体，已被公认为恶性肿瘤的一个标志物，约70%的实体瘤中存在非整倍体。在大多数实体瘤中，人们的共识是，非整倍体肿瘤的存在预示着总体生存率较低和无病间期较短，这表明二倍体肿瘤患者的预后比非整倍体肿瘤患者更有利。因此，DNA含量异常的预后意义表明，在乳腺癌、结肠癌和直肠癌、膀胱浅表癌和恶性黑色素瘤的I期和II期癌中，复发风险更高、生存率恶化或疾病进展风险更大。因此，细胞DNA含量的评估应被视为一个额外的预后决定因素，并应在恶性疾病患者的治疗决策中发挥辅助作用。随着更先进技术的引入，除了一系列肿瘤标志物（如癌胚抗原）和各种癌基因产物外，还可以同时检测DNA倍体和细胞周期分布，从而进一步了解实体瘤细胞的异质性。
